1 tracked superinvestor hold Protagonist Therapeutics Inc (PTGX), worth $26M combined, led by Stanley Druckenmiller. Smart money is accumulating PTGX as of the latest 13F filings.
Current price
$145.72
+144.5%
1Y
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for…
Market cap
$6.3B
P/E
-47.99
Div yield
0.0%
Revenue YoY
-89.4%
Analyst target
$164
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$26M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating PTGX: 1 funds added or opened versus 0 trimming.
Protagonist Therapeutics Inc (PTGX) is held by 1 tracked funds worth $26M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Stanley Druckenmiller at 0.5% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 1 added and 0 trimmed, a net add.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Added | 0.5% | $26M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
1 insider filed SEC Form 144 for $8M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Asif Ali | Officer | 58,629 | $8M | 2026-09-30 |
Which superinvestors own PTGX?
1 tracked funds hold Protagonist Therapeutics Inc (PTGX), the largest being Stanley Druckenmiller (Duquesne Family Office) at 0.5% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling PTGX?
In the most recent 13F quarter, 1 tracked fund added or opened PTGX and 0 trimmed it.
How much PTGX do tracked funds hold?
Combined disclosed long exposure to PTGX across tracked superinvestors is $26M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.